NasdaqCM · Biotechnology

Oramed Pharmaceuticals (ORMP)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Not covered+29.9%

$6.25 average target

$4.81+0.02 (+0.4%)Latest market snapshot · Yahoo Finance

Market cap$200.1M

Cash$50.6M

Quarterly burn$2.9M

Pipeline assets2

Short float2.4%

Clinical portfolio

Oramed Pharmaceuticals Drug Pipeline

Showing 0 of 2

Pipeline data is not currently available

The page remains usable with the verified company and catalyst data already on file.

Continue with BioPharma ProUnlock 2 additional programs and complete development details.

Unlock Pro

Upcoming milestones

ORMP Catalyst Timeline

0 currently tracked

Dated catalysts is not currently available

The page remains usable with the verified company and catalyst data already on file.

Company profile

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.